Shanghaitech University has identified thiazolidinedione compounds acting as DNA methyltransferase 3A (DNMT3A) inhibitors reported to be useful for the treatment of acute myeloid leukemia and overgrowth syndrome.
Hangzhou Healthytide Biotechnology Co. Ltd. has synthesized peptoid compounds targeting integrin α5β1 and/or integrin αvβ5 and/or αvβ6 reported to be useful for the diagnosis and treatment of cancer.
Regor Pharmaceuticals Inc. has divulged phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi, skeletal abnormalities and scoliosis, among others.
CVI Pharmaceuticals Ltd. has identified thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, thyroid cancer, obesity and hypothyroidism.
Hangzhou Polymed Biopharmaceuticals Inc. has synthesized crystalline forms of compounds acting as FLT3 (FLK2/STK1) and interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, neurological and inflammatory disorders.
Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.
Azothbio Inc. and Daegu-Gyeongbuk Medical Innovation Foundation have described non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, cancer, endocrine, inflammatory and neurological disorders.
The University of Michigan has synthesized proteolysis targeting chimeras (PROTACs) comprising a von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to a signal transducer and activator of transcription 3 (STAT3)-targeting moiety via a linker.
RSS